We filed suit on behalf of our client Cancer Therapeutics Laboratories (CTL), a California-based biopharmaceutical company, against a former joint venture partner in a licensing dispute over Tumor Necrosis Therapy (TNT), an antibody technology that locates and kills cancer cells.
The licensing agreement between the two partners stipulated that CTL’s research results and products using TNT technology would be licensed to CTL for use within the Peoples’ Republic of China. But before the product went to market in China, the joint venture partner purported to terminate its licensing agreement with CTL and formed its own subsidiary in China to market its own cancer-therapy product. Our lawsuit alleged wrongful termination of the agreement, breach of contract, breach of good faith and tortious interference with a contract.